Manus Bio publishes on a metabolic engineering framework for efficient and low-cost commercial strain development

CAMBRIDGE, Mass., June 11, 2014 - Manus Bio scientists have published a review article entitled “Multivariate modular metabolic engineering for pathway and strain optimization” in collaboration with Prof. Marjan De Mey from Ghent University. The paper was published in Current Opinion in Biotechnology (

The paper describes the tenets of a novel metabolic engineering framework which enables a low-cost and efficient semi-combinatorial route for developing commercial strains. The core technology was founded by Professor Greg Stephanopoulos (Massachusetts Institute of Technology, MIT) and Dr. Ajikumar Parayil, Ph.D., Co-Founder and Chief Technology Officer of Manus Bio during his time as a research fellow at MIT. “Unlike purely combinatorial approaches which require heavy investments in both library construction and screening, the multivariate modular metabolic engineering approach enables rapid strain optimization through guided semi-combinatorial library design,” says Dr. Ajikumar Parayil. “This means that it has the versatility to be rapidly deployed in a variety of hosts for a number of important pathways and systems.”

About Manus Bio

Manus Bio is a global leader in the use of advanced fermentation technology for manufacturing complex, bioactive natural products as flavors, fragrances, food ingredients, biopesticides, and pharmaceuticals. The core team and technology are from MIT, and the company is headquartered in Cambridge, MA, USA. For more information, visit